In residual nonfunctioning pituitary adenomas, reliable prognostic parameters indicating probability of tumor progression are needed. The Ki 67 expression/MIB-1 labeling index (LI) is considered to be a promising candidate factor. The aim in the present study was to analyze the clinical usefulness of MIB-1 LI for prognosis of tumor progression.
The authors studied a cohort of 92 patients with nonfunctioning pituitary adenomas. Based on sequential postoperative MR images, patients were classified as tumor free (51 patients) or as harboring residual tumor (41 individuals). The residual tumor group was further subdivided in groups with stable residual tumors (14 patients) or progressive residual tumors (27 patients). The MIB-1 LI was assessed in tumor specimens obtained in all patients, and statistical comparisons of MIB-1 LI of the various subgroups were performed.
. The authors found no significant difference of MIB-1 LI in the residual tumor group compared with the tumor-free group. However, MIB-1 LI was significantly higher in the progressive residual tumor group, compared with the stable residual tumor group. Additionally, the time period to second surgery was significantly shorter in residual adenomas showing an MIB-1 LI > 3%.
The data indicate that MIB-1 LI in nonfunctioning pituitary adenomas is a clinically useful prognostic parameter indicating probability of progression of postoperative tumor remnants. The MIB-1 LI may be helpful in decisions of postoperative disease management (for example, frequency of radiographic intervals, planning for reoperation, radiotherapy, and/or radiosurgery).
Abbreviations used in this paper: LI = labeling index; NFPA = nonfunctioning pituitary adenoma; WHO = World Health Organization.
Address correspondence to: Stefan Wolfsberger, M.D., Department of Neurosurgery, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. email:
Please include this information when citing this paper: published online November 7, 2008; DOI: 10.3171/2008.4.17517.
BradleyKMAdamsCBPotterCPWheelerDWAnslowPJBurkeCW: An audit of selected patients with non-functioning pituitary adenoma treated by transsphenoidal surgery without irradiation. Clin Endocrinol (Oxf)41:655–6591994
FerranteEFerraroniMCastrignanoTMenicattiLAnagniMReimondoG: Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol155:823–8292006
GreenmanYTordjmanKSomjenDReider-GroswasserIKohenFOuaknineG: The use of beta-subunits of gonadotrophin hormones in the follow-up of clinically non-functioning pituitary tumours. Clin Endocrinol (Oxf)49:185–1901998
HoneggerJPrettinCFeuerhakeFPetrickMSchulte-MontingJReinckeM: Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg99:674–6792003
Jaffrain-ReaMLDiSDMinnitiGEspositoVBultriniAFerrettiE: A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer9:103–1132002
LosaMFranzinAMangiliFTerreniMRBarzaghiRVegliaF: Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery47:1313–13182000
MastronardiLGuiducciASperaCPuzzilliFLiberatiFMairaG: Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol52:107–1111999
PreusserMHeinzlHGelpiESchoneggerKHaberlerCBirnerP: Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Cancer107:162–1702006
ShibuyaMSaitoFMiwaTDavisRLWilsonCBHoshinoT: Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol84:178–1831992
TanakaYHongoKTadaTSakaiKKakizawaYKobayashiS: Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg98:359–3652003
ThaparKKovacsKScheithauerBWStefaneanuLHorvathEPerniconePJ: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery38:99–1061996
WolfsbergerSKitzKWundererJCzechTBoecher-SchwarzHGHainfellnerJA: Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas. Acta Neurochir (Wien)146:1323–13272004
WolfsbergerSWundererJZachenhoferICzechTBocher-SchwarzHGHainfellnerJ: Expression of cell proliferation markers in pituitary adenomas–correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir (Wien)146:831–8392004
YamadaSOhyamaKTaguchiMTakeshitaAMoritaKTakanoK: A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery61:580–5842007